New Bispecific Antibody Approved for Tough-to-Treat Lymphoma

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

Related Keywords

United States ,Massachusetts ,Sweden ,American ,Swedish ,Mike Bassett ,Krish Patel ,Lymphoma Program ,Genentech ,Swedish Cancer Institute In Seattle ,American Society Of Hematology ,Swedish Cancer Institute ,American Society ,New England Journal ,